CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). 

This milestone was achieved by building on the company's real-world evidence program and dermatology site network of more than 500 investigators, initially developed for the CorEvitas Psoriasis Registry, a collaboration with the National Psoriasis Foundation (NPF). 

Established in 2015, the Psoriasis Registry has enrolled over 14,000 patients at more than 200 sites across the U.S. and Canada to support post-approval safety commitments to the FDA for multiple recently approved biologic therapies. 

In addition, the registry has generated 19 manuscripts and 91 abstracts on studies evaluating the effectiveness of psoriasis treatments, their impact on quality of life, and characterizations of patient sub-populations.

Similar studies are expected from the CorEvitas AD Registry, with more than 1,000 patients enrolled since the registry launch nine months ago. Dr. Jonathan Silverberg, Associate Professor of Dermatology, George Washington University School of Medicine and Health Sciences in Washington, DC, and Dr. Eric Simpson, Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland serve as Scientific Co-Directors of the registry. The registry has been designed to fill a major gap in real-world evidence generation for patients with AD on drug effectiveness and safety, collecting a comprehensive dataset on disease phenotypes, comorbidities, treatment effectiveness, quality of life, and long-term drug safety. 

"There is immense value in the independent CorEvitas dermatology registries in their robust and longitudinal collection of validated clinical outcomes and patient reported outcomes, which enables us to evaluate and contextualize the real-world safety and effectiveness of approved therapies," says Dr. Silverberg in a news release.

"We are truly grateful to the NPF and the dermatology investigator network that we have built, uniquely positioning CorEvitas to study a range of immune-mediated skin conditions to benefit our patients," adds Dr. Jeff Greenberg, Chief Medical Officer of CorEvitas.